SBIR/STTR Research Award
Evaluation of Sodium Channel Inhibitors as Therapeutics for Chronic Muscle Disord
Award amount
$223,808Program and phase
SBIR · Phase IAward year
2013Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PROGNOSYS BIOSCIENCES, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- PA12-088
- Topic code
- NIAID
Research abstract
DESCRIPTION (provided by applicant): There is a need for new proteomics technologies to enable multiplexed assays of immune system response. We aim to develop a novel technology for this application that is based on simultaneously measuring the binding ofmany customizable in silico-defined peptides. This technology could be applied to identify epitopes from pathogens, autoantigens, allergens or tumors for use in vaccine design and monitoring of immune responses. PUBLIC HEALTH RELEVANCE PUBLIC HEALTHRELEVANCE: This proposal aims to establish a novel, high-throughput tool that can identify the particular components of a given pathogen, autoantigen, allergen or tumor that are best presented to the immune system by an individual. This tool could be usedfor vaccine design and monitoring of immune responses. More generally, the technology in this proposal would enable a novel approach for measuring inter-individual variation in the immune response.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients